Clinical Trial Update: MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing MabionCD20 to MabThera in rheumatoid arthritis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MabThera (rituximab)
• MabionCD20 (MabionCD20)

Snippet

Sponsor: Mabion SA | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED